(Q44448309)

English

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

scientific article published in June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Amedeo Mugellini

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Leonardina Ciccarelli

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Giuseppe Crescenzi

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Roberto Fogari

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Diabetes Research and Clinical Practice

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

161-169

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Improving the adverse cardiovascular prognosis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies for the management of diabetic dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk in diabetes: a brief review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin and Cardiovascular Disease: Paris Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Implications of the UK prospective diabetes study: questions answered and issues remaining

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes: role of metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved endothelial function with metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative tolerability of sulphonylureas in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Exercise adds to metformin and acarbose efficacy in db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900057-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8227(03)00057-3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44448309&oldid=2024473427"